Effects of pioglitazone and retinoic acid in a rotenone model of Parkinson's disease

Ulusoy, Kemal Gokhan; Çelik, Turgay; Kayır, Hakan; Gürsoy, Murat; Işık, Ahmet Turan; Uzbay, Tayfun

doi:10.1016/j.brainresbull.2011.05.001

Cited by 55 publications

(33 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Pioglitazone Anti-inflammatory Enhances mitochondrial bioenergetics Improved motor and behavioural symptoms, reduced microglial activation and DA cell loss in lipopolysaccharide, rotenone and MPTP nonhuman primate models 89,90,209 No clinical data; phase II trial currently underway AZD3241 Anti-inflammatory Inhibits myeloperoxidase Reduces α-synuclein aggregation…”

Section: Calcium Channel Blockadementioning

confidence: 99%

The ongoing pursuit of neuroprotective therapies in Parkinson disease

2014

View full text Add to dashboard Cite

Many agents developed for neuroprotective treatment of Parkinson disease (PD) have shown great promise in the laboratory, but none have translated to positive results in patients with PD. Potential neuroprotective drugs, such as ubiquinone, creatine and PYM50028, have failed to show any clinical benefits in recent high-profile clinical trials. This 'failure to translate' is likely to be related primarily to our incomplete understanding of the pathogenic mechanisms underlying PD, and excessive reliance on data from toxin-based animal models to judge which agents should be selected for clinical trials. Restricted resources inevitably mean that difficult compromises must be made in terms of trial design, and reliable estimation of efficacy is further hampered by the absence of validated biomarkers of disease progression. Drug development in PD dementia has been mostly unsuccessful; however, emerging biochemical, genetic and pathological evidence suggests a link between tau and amyloid-β deposition and cognitive decline in PD, potentially opening up new possibilities for therapeutic intervention. This Review discusses the most important 'druggable' disease mechanisms in PD, as well as the most-promising drugs that are being evaluated for their potential efficiency in treatment of motor and cognitive impairments in PD.

show abstract

Section: Calcium Channel Blockadementioning

confidence: 99%

The ongoing pursuit of neuroprotective therapies in Parkinson disease

2014

View full text Add to dashboard Cite

show abstract

“…Rotenone signifi cantly reduced locomotor activity of the rats and also signifi cantly reduced dopamine levels in the striatum and hippocampus. Pioglitazone, but not retinoic acid, signifi cantly reversed the reduced striatal dopamine level [ 59 ]. Isradipine, a dihydropyridine calcium channel blocker (DiCCB), has also been shown to be neuroprotective in preclinical models of parkinsonism.…”

Section: Infl Ammation and Pdmentioning

confidence: 99%

Parkinson’s Disease: An Overview of Etiology, Clinical Manifestations, and Treatment

Dalvi

Lyons

Pahwa

2014

Inflammation in Parkinson's Disease

View full text Add to dashboard Cite

“…55 In animal models of PD on the other hand, treatment with retinoic acid reduced degeneration of dopaminergic neurons 56 and alleviated motor symptoms. 57 Similar to PD, direct evidence for aberrant retinol/ retinoic acid signaling has not been found in multiple sclerosis. Many recent studies, however, propose targeting the RA pathway in MS because of its barrier inducing properties, immune quiescence inducing properties, free radical scavenging properties, and anti-inflammatory properties.…”

Section: Retinoic Acidmentioning

confidence: 99%